KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. PMID 37379495 · J Clin Oncol · 2023-Sep-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Protocol for a randomized controlled trial of endoscopic ultrasound guided celiac plexus neurolysis (EUS-CPN) with vs without bupivacaine. PMID 37684697 · Trials · 2023-Sep-08 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Prediction of lung papillary adenocarcinoma-specific survival using ensemble machine learning models. PMID 37684259 · Sci Rep · 2023-Sep-08 This is a retrospective prognostic model study using a public database (SEER) to predict cancer-specific survival in lung papillary adenocarcinoma. It is not a randomized clinical trial comparing drug interventions, does not report a primary efficacy endpoint from a Phase III/IIIb or Phase II/III trial, and is not an original result report of a clinical trial. The 'Randomized Controlled Trial' publication type is incorrect based on the abstract content.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Inflammatory and Metabolic Biomarker Assessment in a Randomized Presurgical Trial of Curcumin and Anthocyanin Supplements in Patients with Colorectal Adenomas. PMID 37764678 · Nutrients · 2023-Sep-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Motivational interviewing to promote healthy behaviors for obesity prevention in young adults (MOTIVATE): a pilot randomized controlled trial protocol. PMID 37679845 · Pilot Feasibility Stud · 2023-Sep-07 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Towards patient-led follow-up after curative surgical resection of stage I, II and III colorectal cancer (DISTANCE-trial): a study protocol for a stepped-wedge cluster-randomised trial. PMID 37679735 · BMC Cancer · 2023-Sep-07 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Colorectal Cancer Screening Decision Based on Predicted Risk: Protocol for a Pilot Randomized Controlled Trial. PMID 37676720 · JMIR Res Protoc · 2023-Sep-07 The record is a protocol for a pilot randomized controlled trial on colorectal cancer screening. It is not a Phase III/IIIb or Phase II/III randomized trial with results. The intervention compares personalized risk communication and screening recommendations versus usual care, not a drug intervention. The primary outcome is screening uptake (a process measure), not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the eligibility criteria for the KM digitization cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Molecular testing to deliver personalised chemotherapy recommendations. PMID 37674128 · BMC Med · 2023-Sep-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial. PMID 37226534 · Oncologist · 2023-Sep-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results. PMID 37196069 · Oncologist · 2023-Sep-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. PMID 37104870 · Oncologist · 2023-Sep-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Establishment of a Seven-Gene Signature Associated with CD8+ T Cells through the Utilization of Both Single-Cell and Bulk RNA-Sequencing Techniques in Clear Cell Renal Cell Carcinoma. PMID 37762031 · Int J Mol Sci · 2023-Sep-06 The study is a retrospective bioinformatic analysis of public databases (TCGA, GEO) to establish a prognostic gene signature, not a report of a randomized controlled drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Conditional Risks of Biochemical Failure and Prostate Cancer-Specific Death in Patients Undergoing External Beam Radiotherapy: A Secondary Analysis of 2 Randomized Clinical Trials. PMID 37751207 · JAMA Netw Open · 2023-Sep-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. PMID 37721754 · JAMA Netw Open · 2023-Sep-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Antidepressant Use and Mortality Among Patients With Hepatocellular Carcinoma. PMID 37672269 · JAMA Netw Open · 2023-Sep-05 The study is an observational cohort study, not a randomized controlled trial, and does not report a Phase III/IIIb or Phase II/III trial design. Although it assesses a drug intervention (antidepressants) and a time-to-event endpoint, it fails the key eligibility criteria for randomized trial phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and efficacy of P2Et extract from Caesalpinia spinosa in breast cancer patients: study protocol for a randomized double blind phase II clinical trial (CS003-BC). PMID 37670337 · BMC Complement Med Ther · 2023-Sep-05 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer. PMID 37666855 · Nat Commun · 2023-Sep-04 The record describes a secondary analysis (biomarker discovery framework) applied to data from the FIRE-3 phase III trial, but it does not present the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) of the trial itself. Therefore, it is not an eligible primary result report of an RCT with a time-to-event endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial. PMID 37658083 · Nat Commun · 2023-Sep-02 Record describes a Phase I trial of atezolizumab plus SABR. It is randomized. While it includes a drug intervention and original results, the primary endpoint is maximum tolerated dose (MTD), and efficacy signals are described generically without formal time-to-event data. The deterministic review flagged no time_to_event_signal, confirming this.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. PMID 37451295 · Lancet · 2023-Sep-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Erector spinae plane block versus intercostal nerve block for postoperative analgesia in lung cancer surgery. PMID 37665743 · Radiol Oncol · 2023-Sep-01 The study is a randomized controlled trial in oncology (lung cancer surgery) with human subjects and reports original results, but it is excluded because it does not meet key eligibility criteria: it does not involve a drug-containing intervention (it compares two anesthetic nerve block techniques, not a systemic or targeted drug therapy), it does not report a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP with Kaplan-Meier analysis or hazard ratios, and it is not specified as a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study. PMID 37494583 · Radiol Oncol · 2023-Sep-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Erratum: Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. PMID 37450783 · J Clin Oncol · 2023-Sep-01 The record is a published erratum, not an original formal result report. While the title describes a randomized Phase III drug trial in oncology, the erratum publication type and lack of abstract content prevent confirmation of a primary/key secondary time-to-event efficacy endpoint. Metadata cannot establish human subject data.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. PMID 37440239 · JAMA Oncol · 2023-Sep-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial. PMID 37432976 · Clin Cancer Res · 2023-Sep-01 The record reports results from a biomarker/prognostic subgroup analysis of the GeparSepto trial, focusing on CAV1/2 expression, not the primary comparative efficacy report of the randomized trial itself. While the underlying trial is randomized and involves drug interventions, the phase is not explicitly confirmed in the provided information, and this specific report is a secondary, biomarker-focused analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial. PMID 37410476 · JAMA Oncol · 2023-Sep-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. PMID 37369081 · J Clin Oncol · 2023-Sep-01 The study is an oncology, human, randomized trial with a drug intervention, but it is a Phase Ib/II study (not Phase III/IIIb or Phase II/III) and does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or time-to-event analysis. The primary endpoint is objective response rate (cORR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. PMID 37352476 · J Clin Oncol · 2023-Sep-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial. PMID 37325931 · Ann Surg · 2023-Sep-01 The study is a randomized, prospective oncology trial with a time-to-event endpoint (LRFS) and is an original research report. However, it is excluded because it does not meet two required criteria: 1) The study compares surgical procedures (breast-conserving surgery vs. mastectomy) after neoadjuvant chemotherapy; it does not have a drug-containing intervention as a primary comparator (the neoadjuvant chemotherapy was common to all patients). 2) The trial phase is not confirmed as Phase III/IIIb or Phase II/III; I-SPY2 is a well-known adaptive Phase II platform trial, which does not meet the definitive phase requirement.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized Study. PMID 37055279 · Int J Radiat Oncol Biol Phys · 2023-Sep-01 The record describes a randomized trial in pancreatic cancer with OS and RFS endpoints and a drug intervention (gemcitabine). However, the trial phase is not explicitly stated in the provided metadata (title, abstract, publication types, MeSH) to confirm it meets the Phase III/IIIb or Phase II/III criterion. The deterministic review also flags this as unclear. Without explicit phase evidence, eligibility cannot be confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial). PMID 37037359 · Int J Radiat Oncol Biol Phys · 2023-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Dosimetric Evaluation of Organs at Risk From SAVE Protocol. PMID 37023988 · Int J Radiat Oncol Biol Phys · 2023-Sep-01 The record is a Phase III randomized trial in oncology but does not meet eligibility criteria because: 1) it lacks a primary/key secondary time-to-event efficacy endpoint (no OS, PFS, DFS, etc., or KM/HR analysis); and 2) the intervention is a radiation therapy (brachytherapy) protocol, not a drug-containing intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial. PMID 37014660 · Clin Cancer Res · 2023-Sep-01 The record describes a biomarker subgroup analysis of mutation status on survival outcomes within a randomized trial. While the trial itself is randomized and includes drug intervention with time-to-event endpoints, the record's primary purpose is an exploratory analysis of genetic factors, not a report of the trial's formal primary or key secondary efficacy results. The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. Therefore, it does not meet the criteria for inclusion as a formal result report of a Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of calcium and vitamin D supplementation with cancer incidence and cause-specific mortality in Black women: Extended follow-up of the Women's Health Initiative calcium-vitamin D trial. PMID 36650676 · Int J Cancer · 2023-Sep-01 The study is a randomized clinical trial with time-to-event endpoints, but the intervention is a dietary supplement (calcium and vitamin D) for primary prevention, not a drug for cancer treatment. Therefore, it does not meet the key inclusion criterion of a drug-containing intervention in an oncology context.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and Validation of a Tool to Identify Patients Diagnosed With Castration-Resistant Prostate Cancer. PMID 37862671 · JCO Clin Cancer Inform · 2023-Sep The record describes a methodological study to validate a patient identification tool for castration-resistant prostate cancer. It is not a clinical trial report of a drug intervention with time-to-event efficacy outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial. PMID 37810112 · Heliyon · 2023-Sep 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Comparative Effectiveness Analysis of Lumpectomy and Mastectomy for Elderly Female Breast Cancer Patients: A Deep Learning-based Big Data Analysis. PMID 37781001 · Yale J Biol Med · 2023-Sep The study is an emulated trial using observational data (SEER-Medicare) to compare surgical procedures, not a randomized controlled trial with a drug intervention. It lacks explicit evidence of being a Phase III/IIIb or Phase II/III trial with a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial. PMID 37744711 · JGH Open · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. PMID 37728779 · J Neurooncol · 2023-Sep The record reports a post-hoc subgroup and MRI analysis of a randomized trial, not the original primary result report. While the underlying trial (CeTeG/NOA-09) is likely Phase III, the abstract does not explicitly confirm the phase, and the analysis itself is secondary/exploratory in nature.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Analgesic efficacy of an opioid-free postoperative pain management strategy versus a conventional opioid-based strategy following open major hepatectomy: an open-label, randomised, controlled, non-inferiority trial. PMID 37692074 · EClinicalMedicine · 2023-Sep The study is a randomized, controlled trial in oncology patients (HCC) but evaluates postoperative pain management (non-inferiority of opioid-free analgesia) with a continuous primary endpoint (pain AUC). It lacks the required time-to-event efficacy endpoint (e.g., OS, PFS) and associated analyses (Kaplan-Meier, HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
EFFICACY AND SAFETY OF A DEXAMETHASONE-BASED MOUTHWASH TO PREVENT CHEMOTHERAPY-INDUCED STOMATITIS IN WOMEN WITH BREAST CANCER: A MULTICENTRE, OPEN-LABEL, RANDOMISED PHASE 2 STUDY. PMID 37689451 · J Evid Based Dent Pract · 2023-Sep Study is a Phase 2 randomized trial with a drug intervention, but the primary endpoint is incidence (a binary outcome), not a time-to-event efficacy endpoint. It does not meet the definitive phase or time-to-event endpoint criteria.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial. PMID 37670901 · Mol Genet Metab Rep · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Role of reduction gastrectomy in patients with gastric cancer with a single non-curable factor: Supplementary analysis of REGATTA trial. PMID 37663970 · Ann Gastroenterol Surg · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022. PMID 37662522 · EClinicalMedicine · 2023-Sep The record is a meta-analysis/regulatory review of pre-approval evidence for 72 cancer indications granted conditional approval in China. It synthesizes results from multiple underlying trials (74% single-arm, 26% randomized) but is not an original result report of a single definitive randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. PMID 37661097 · J Immunother Cancer · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study. PMID 37659419 · Lancet Microbe · 2023-Sep The study is a prospective cohort analysis nested within a randomized trial of convalescent plasma for COVID-19. It evaluates inflammatory markers (cytokines/chemokines) by vaccination status, not a drug intervention efficacy endpoint for oncology. There is no mention of overall survival, progression-free survival, or any time-to-event outcome. The study is not oncology-focused.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. PMID 37657461 · Lancet Oncol · 2023-Sep The study is an exploratory analysis of a large, randomized ovarian cancer screening trial. It is oncology and human, and randomized. However, it is not a Phase III therapeutic trial of a drug intervention; the primary intervention is screening. The survival analysis is presented for a subgroup of patients with high-grade serous cancer and is not the primary/key secondary endpoint of a Phase III drug trial. Therefore, it does not meet the criteria for a drug-containing Phase III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study. PMID 37646150 · Acta Oncol · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A randomised trial of [18F]PSMA-1007-PET/CT versus NaF-PET/CT for staging primary prostate cancer: A trial protocol. PMID 37636207 · BJUI Compass · 2023-Sep 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. PMID 37614053 · J Clin Hypertens (Greenwich) · 2023-Sep The study is a randomized Phase III trial for hypertension with drug intervention and original results. However, it is not an oncology study and the primary endpoint (change in systolic blood pressure) is not a time-to-event outcome. No oncology-specific time-to-event endpoint (OS, PFS, etc.) or Kaplan-Meier analysis is reported.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. PMID 37592104 · Nat Med · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -